KAEL–GemVax Reports Encouraging Interim Progress in Phase II Study of GV1001 Anti-telomerase Vaccine in NSCLC
11/15/2011 6:27:23 AM
More...
|
KAEL–GemVax: TeloVac Becomes World’s Largest Ever Pancreatic Cancer Vaccine Trial
5/5/2011 10:58:54 AM
More...
|
Lytix Biopharma and KAEL–GemVax Announce First Patient Treated in Clinical Trial to Combine LTX-315 and GV1001 Cancer Vaccine Immunotherapy
12/6/2010 11:50:35 AM
More...
|
KAEL–GemVax Reports Significant Interim Progress In UK Telovac Phase III Study Of GV1001 Anti-Telomerase Vaccine In Pancreatic Cancer
7/12/2010 10:47:47 AM
More...
|
Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy
6/8/2010 10:54:48 AM
More...
|